Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study

OBJECTIVE: To evaluate the efficacy and safety of atacicept, an antagonist of B lymphocyte stimulator/APRIL–mediated B cell activation, in patients with systemic lupus erythematosus (SLE). METHODS: ADDRESS II is a 24‐week, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐arm, phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Merrill, Joan T., Wallace, Daniel J., Wax, Stephen, Kao, Amy, Fraser, Patricia A., Chang, Peter, Isenberg, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099253/
https://www.ncbi.nlm.nih.gov/pubmed/29073347
http://dx.doi.org/10.1002/art.40360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099253/
https://www.ncbi.nlm.nih.gov/pubmed/29073347
http://dx.doi.org/10.1002/art.40360

Ejemplares similares